These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17431851)

  • 41. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of a composite endpoint for randomized controlled trials in liver surgery.
    van den Broek MA; van Dam RM; van Breukelen GJ; Bemelmans MH; Oussoultzoglou E; Pessaux P; Dejong CH; Freemantle N; Olde Damink SW
    Br J Surg; 2011 Aug; 98(8):1138-45. PubMed ID: 21557208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring a three-armed clinical trial with survival endpoints: Fisher's least significant difference approach.
    Chen PL; Dominik R
    J Biopharm Stat; 2004 Aug; 14(3):791-801. PubMed ID: 15468765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomes.
    Ji Y; Bekele BN
    Biometrics; 2009 Sep; 65(3):876-84. PubMed ID: 19173694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Handling missing data in vaccine clinical trials for immunogenicity and safety evaluation.
    Li X; Wang WW; Liu GF; Chan IS
    J Biopharm Stat; 2011 Mar; 21(2):294-310. PubMed ID: 21391003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonparametric estimation in a Markov "illness-death" process from interval censored observations with missing intermediate transition status.
    Frydman H; Szarek M
    Biometrics; 2009 Mar; 65(1):143-51. PubMed ID: 18505421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components.
    Bofill Roig M; Gómez Melis G
    Stat Med; 2019 May; 38(11):1935-1956. PubMed ID: 30637797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new endpoint definition improved clinical relevance and statistical power in a vaccine trial.
    Pédrono G; Thiébaut R; Alioum A; Lesprit P; Fritzell B; Lévy Y; Chêne G
    J Clin Epidemiol; 2009 Oct; 62(10):1054-61. PubMed ID: 19282146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice.
    Otero-Fernández R; Gómez-Outes A; Martínez-González J; Rocha E; Fontcuberta J;
    Clin Appl Thromb Hemost; 2008 Jan; 14(1):75-83. PubMed ID: 17895506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Easily applicable multiple testing procedures to improve the interpretation of clinical trials with composite endpoints.
    Schüler S; Mucha A; Doherty P; Kieser M; Rauch G
    Int J Cardiol; 2014 Jul; 175(1):126-32. PubMed ID: 24861257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials.
    Kang S; Yang Y; Li CJ; Gao R
    Clin Ther; 2007 Nov; 29(11):2406-18. PubMed ID: 18158081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Another view on the analysis of cardiovascular morbidity/mortality trials.
    Rosenkranz GK
    Pharm Stat; 2011; 10(3):196-202. PubMed ID: 21574240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alternative methods to evaluate trial level surrogacy.
    Abrahantes JC; Shkedy Z; Molenberghs G
    Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Constructing multiple test procedures for partially ordered hypothesis sets.
    Edwards D; Madsen J
    Stat Med; 2007 Dec; 26(28):5116-24. PubMed ID: 17476650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A consistency-adjusted alpha-adaptive strategy for sequential testing.
    Alosh M; Huque MF
    Stat Med; 2010 Jul; 29(15):1559-71. PubMed ID: 20552571
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes.
    Hu M; Cappelleri JC; Lan KK
    Clin Trials; 2007; 4(4):329-40. PubMed ID: 17848494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of methods for analyzing a binary composite endpoint with partially observed components in randomized controlled trials.
    Pham TM; White IR; Kahan BC; Morris TP; Stanworth SJ; Forbes G
    Stat Med; 2021 Dec; 40(29):6634-6650. PubMed ID: 34590333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.